Amer Kassar, MD
Endocrinology, Diabetes & Metabolism · Dekalb, ILNPI 1932208063
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,023 of the $143,488 with a category attached, or 62.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.0%. Reporting peaked in 2019 at $55,880 and has fallen 89.6% since, to $5,802 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,106 payments — averaging $68.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$23K
- Dexcom, Inc.$16K
- Boehringer Ingelheim$15K
- Merck$12K
- Xeris Pharmaceuticals, Inc.$9K
- Johnson & Johnson$9K
- plus $60K from 54 others
What the payments were for
- Consulting fees$9,6607%
- Speaking & faculty fees$89,02362%
- Travel & lodging$5,3454%
- Food & beverage$39,20527%
- Education$780%
- Gifts$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$19,263
- SOLIQUA 100/33$15,782
- TOUJEO$11,201
- STEGLATRO$10,920
- DEXCOM G7 GSS (161)$9,319
- INVOKANA$8,520
- GVOKE HYPOPEN$8,414
- FARXIGA$7,004
- CeQur Simplicity$5,930
- DEXCOM G6 TRANSMITTER$5,584
- Kerendia$5,454
- Korlym$3,634
- ZEGALOGUE$863
- FREESTYLE LIBRE 3$614
- INPEN SMART INSULIN DELIVERY SYSTEM$494
- FreeStyle Libre Pro$406
- AFREZZA$248
- Omnipod$224
- MINIMED 780G$138
- REZDIFFRA$124
How this compares
$143,488 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 975 | $1,552,853 |
| JardianceEmpagliflozin | 339 | $352,458 |
| MounjaroTirzepatide | 224 | $347,569 |
| FarxigaDapagliflozin Propanediol | 272 | $289,352 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 155 | $87,925 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $75,224 |
| JanuviaSitagliptin Phosphate | 93 | $74,051 |
| TrulicityDulaglutide | 48 | $71,276 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $66,905 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 110 | $64,814 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $64,706 |
| SynthroidLevothyroxine Sodium | 644 | $57,818 |
| Humalog Kwikpen U-100Insulin Lispro | 150 | $52,726 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $46,714 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 328 | $44,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $3,015 | $1,597,2821,009 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $8,662 | $438,172332 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14,881 | $368,038360 claims |
| AstraZenecaFarxiga | $8,171 | $289,352272 claims |
| MerckJanuvia, Janumet Xr, Janumet | $11,798 | $109,213130 claims |
| AbbVieSynthroid | $1,568 | $57,818644 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $22,923 | $46,71428 claims |
| Mannkind CorporationAfrezza | $2,064 | $26,02019 claims |
| Cequr CorporationCequr Simplicity | $5,944 | $21,45830 claims |
| Antares Pharma, Inc.Xyosted | $800 | $15,35213 claims |
| PfizerGenotropin | $38 | $11,05013 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $439 | $10,7981,417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Dekalb
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.